Targeting tachykinin receptors in neuroblastoma by Henssen, Anton G et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
Targeting tachykinin receptors in neuroblastoma
Anton G. Henssen1,*, Andrea Odersky2,*, Annabell Szymansky3, Marleen Seiler4, 
Kristina Althoff2, Anneleen Beckers5, Frank Speleman5, Simon Schäfers2, Katleen 
De Preter5, Kathy Astrahanseff3, Joachim Struck4, Alexander Schramm2, Angelika 
Eggert3,6, Andreas Bergmann4, Johannes H. Schulte3,6
1Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
2Department of Pediatric Oncology and Hematology, University Children`s Hospital Essen, Germany
3Department of Pediatric Oncology/Hematology, Charité- Universitätsmedizin Berlin, Germany
4Sphingotec GmbH, Hennigsdorf, Germany
5Center of Medical Genetics Ghent (CMGG), Ghent University Hospital, Belgium
6German Consortium for Translational Cancer Research (DKTK), Partner Site Charite Berlin, Berlin, Germany
*These authors contributed equally to this work
Correspondence to: Anton Henssen, email: henssena@mskcc.org 
Keywords: fosaprepitant, aprepitant, neuroblastoma, NK1R, targeted therapy
Received: June 29, 2016    Accepted: November 12, 2016    Published: November 18, 2016
ABSTRACT
Neuroblastoma is the most common extracranial tumor in children. Despite 
aggressive multimodal treatment, high-risk neuroblastoma remains a clinical challenge 
with survival rates below 50%. Adding targeted drugs to first-line therapy regimens 
is a promising approach to improve survival in these patients. TACR1 activation by 
substance P has been reported to be mitogenic in cancer cell lines. Tachykinin receptor 
(TACR1) antagonists are approved for clinical use as an antiemetic remedy since 2003. 
Tachykinin receptor inhibition has recently been shown to effectively reduce growth of 
several tumor types. Here, we report that neuroblastoma cell lines express TACR1, and 
that targeting TACR1 activity significantly reduced cell viability and induced apoptosis 
in neuroblastoma cell lines. Gene expression profiling revealed that TACR1 inhibition 
repressed E2F2 and induced TP53 signaling. Treating mice harboring established 
neuroblastoma xenograft tumors with Aprepitant also significantly reduced tumor 
burden. Thus, we provide evidence that the targeted inhibition of tachykinin receptor 
signaling shows therapeutic efficacy in preclinical models for high-risk neuroblastoma.
INTRODUCTION
Neuroblastoma is the most common extracranial 
solid tumor in children. Polychemotherapy is a well-
established part of first-line therapy for patients with 
metastatic neuroblastomas [1]. However, long-term 
adverse side effects are a problem for survivors and 
curative treatment remains unsuccessful with standard 
first-line treatment in most high-risk cases [2]. Additional 
therapeutic strategies that lower toxicity and/or improve 
efficacy of current treatment, such as novel drug 
combination regimens are desperately needed to improve 
survival and long-term quality of life during long-term 
survival in high-risk neuroblastoma patients. 
Aprepitant (Emend) is approved by the Food and 
Drug Administration (FDA) and the European Medicines 
Agency (EMA) for the treatment of chemotherapy-
induced nausea and vomiting and is orally administered 
[3, 4]. Fosaprepitant (Ivemend), is a water-soluble 
phosphoryl prodrug of aprepitant, which is intravenously 
administered [5]. Currently, these drugs are used in 
clinical practice as antiemetics for neuroblastoma 
patients receiving emetogenic chemotherapy agents 
including platinum-based chemotherapeutics [3], 
and no considerable side effects have been observed. 
Pharmacokinetic analysis showed that intravenous 
administration of 115 mg fosaprepitant in patients results 
in peak concentrations of ~3000 ng/ml blood, equivalent 
to approximately a 5 µM concentration in circulating 
blood leading to over 90% TACR1 receptor occupancy by 
aprepitant. In clinical trials a maximum tolerated dose was 
not defined and no side effects were observed at single 
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doses up to 1000 mg. Thus, high aprepitant concentrations 
are tolerated without causing considerable side effects [5].
The tachykinin receptor, TACR1 (formerly NK1R), 
is a specific G protein-coupled receptor [6, 7] and is 
expressed in many different cell types that respond 
to tachykinins in a cell type-specific manner. TACR1 
is linked to a variety of physiological and biological 
processes that include the regulation of neurotransmission, 
pain, inflammation, cell growth and differentiation [8, 9]. 
Some recent studies have proposed tachykinin receptor 
involvement in oncogenesis [10–14]. TACR1 activation 
by substance P initiates phosphoinositide hydrolysis 
to mobilize intracellular calcium and active calcium-
dependent signaling via kinases, such as the SRC kinase 
[15, 16]. Aprepitant and fosaprepitant act as antagonists 
of substance P to selectively antagonize TACR1 signaling 
[3]. Pharmaceutically blocking tachykinin receptor 
signaling in colon cancer, breast cancer, hepatoblastoma, 
osteosarcoma, acute lymphoblastic leukemia and 
neuroblastoma cancer cell lines was found to inhibit 
cell growth, and treatment of mice with osteosarcoma 
xenografts resulted in reduced tumor burden. This 
previous evidence makes tachykinin receptors a putative 
target for future anticancer strategies [10, 12, 14].
Although neuroblastoma patients often receive 
aprepitant during treatment, little is known about what 
effect this might have on the tumor itself. Encouraged 
by recent observations of antitumor effects of tachykinin 
receptor antagonists in various cancer cell lines, we 
investigated the role of TACR1 in high-risk neuroblastoma 
and explored whether targeting TACR1 could be a 
therapeutic option in this disease. 
RESULTS
TACR1 and its downstream targets SRC 
and p-SRC are expressed in a subset of 
neuroblastoma cell lines 
TACR1 expression was examined in a panel of 
neuroblastoma cell lines as well as fibroblast control cells 
using western blotting and quantitative RT-PCR. TACR1 
protein was expressed in all human neuroblastoma cell 
lines assessed, although expression levels varied between 
cell lines, with SY5Y expressing only low levels and IMR5 
strongly expressing TACR1 (Figure 1A, 1B and 1E). Non-
transformed fibroblast cells also expressed TACR1 protein 
(Figure  1A and 1E). To assess TACR1 activity in these 
cells we measured SRC and phosphorylated SRC (p-SRC) 
protein expression using western blotting. IMR5, SK-N-
BE and Kelly cells expressed the highest levels of p-SRC 
whereas SY5Y and Shep cells only expressed low levels 
of p-SRC, indicating different levels of SRC activation in 
these cells. No measureable p-SRC was detected in non-
transformed fibroblasts. Based on the observed TACR1 
expression and previous reports of TACR1 mitogenic 
properties in other tumor entities we hypothesized that 
TACR1 activity might exhibit mitogenic functions in a 
subset of neuroblastoma cells through activation of SRC 
and other downstream targets and that pharmaceutically 
inhibiting TACR1 could be a therapeutic option in these 
cells.
Inhibition of TACR1 signaling inhibits cell 
growth and leads to increased cell death 
To inquire whether TACR1 signaling leads to increased 
proliferative capacity in neuroblastoma cells, we treated 
IMR5 cells, which express high levels of TACR1 as well as 
high levels of p-SRC, with the TACR1 ligand, substance P. 
Treatment with substance P increased the relative number of 
viable IMR5 cells over time in 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assays (Figure 2A), 
suggesting that TACR1 activity might be required for IMR5 
cell survival. To assess the effect of TACR1 inhibition on 
neuroblastoma cell viability, we treated cells in vitro with 
the water soluble aprepitant analog, fosaprepitant, and 
assessed cell viability relative to untreated control cultures 
in MTT assays. All neuroblastoma cell lines tested exhibited 
a concentration-dependent reduction in cell viability 
in response to TACR1 inhibition (Figure  2B and 2C), 
although sensitivity varied strongly among cell lines. While 
untransformed fibroblasts tolerated high concentrations of 
fosaprepitant (IC50 = 44 μM), only 0.85 μM fosaprepitant 
was needed to induce 50% growth inhibition (IC50) in SK-
N-AS cells, indicating a specific effect on malignant cells 
(Figure 2B and 2C). In addition to assessing cell viability, 
we investigated proliferative capacity directly by measuring 
BrdU incorporation in 3 cell lines after fosaprepitant 
treatment in comparison to untreated control cultures. Cells 
lines were selected that expressed different levels of TACR1 
and p-SRC and that spanned the fosaprepitant sensitivity 
range identified by assessing cell viability, namely SK-N-
AS (highly sensitive), IMR5 (intermediately sensitive) 
and SY5Y (relatively insensitive). BrdU incorporation 
was significantly suppressed after fosaprepitant treatment 
(Figure  2E). Interestingly, the most pronounced reduction 
in BrdU incorporation occurred in IMR5 cells, which 
express the highest TACR1 and p-SRC levels of the 3 cell 
lines whereas SY5Y cells expressing low levels of TACR1 
and p-SRC showed relative resistance to fosaprepitant 
treatment. We next assessed whether fosaprepitant treatment 
also induced cell death by measuring the relative amount 
of cytoplasmic histone-associated DNA fragments in cells 
treated with fosaprepitant compared to untreated control 
cells. Fosaprepitant treatment significantly increased 
the relative amount of histone-associated DNA in all 3 
neuroblastoma cell lines tested, indicating that fosaprepitant 
induces cell death (Figure  2F). Again, IMR5 cells showed 
the most pronounced increase in cell death, suggesting 
that fosaprepitant effects on neuroblastoma cells might be 
dependent on TACR1 signaling activity. 
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Inhibition of TACR1 signaling leads to increased 
apoptosis and cell cycle arrest depending on the 
cellular context
Considering the differential anti-tumoral effects of 
fosaprepitant on different neuroblastoma cell lines, we set 
out to assess the cellular mechanisms responsible for the 
antitumoral activity of fosaprepitant. To assess whether 
cells were dying by apoptosis, we flow cytometrically 
assessed cell surface expression of annexin V in all three 
cell lines after treatment with fosaprepitant. Fosaprepitant 
treatment significantly increased both the fraction of 
apoptotic and pre-apoptotic in IMR5 and SK-N-AS cells 
but not in SY5Y cells (Figure 3A). To assess whether the 
differential response of IMR5 and SY5Y cells was due 
to kinetic differences in cell proliferation, we monitored 
real-time cell growth using xCelligence [17]. We observed 
that fosaprepitant led to a decrease in IMR5 cell numbers 
within 48 h after treatment, consistent with induction of 
cell death, whereas SY5Y cells grew exponentially with 
only modestly decreased growth rates at high fosaprepitant 
doses (Figure  3B). To examine the underlying cellular 
processes occurring in cells treated with fosaprepitant, 
we assessed the cell cycle distribution of cells treated 
with fosaprepitant. Consistent with our observation of 
increased cell death and apoptosis in IMR5 and SK-N-AS 
cells, the fraction of IMR5 and SK-N-AS cells in sub-G1 
increased after treatment with fosaprepitant (Figure  3C). 
In SY5Y cells on the other hand, we observed an increase 
in the fraction of cells in G2M phase, consistent with 
reduced induction of apoptosis/cell death (Figure  3C). 
As observed before, only minimal changes in the cell 
cycle distribution of non-transformed fibroblasts were 
observed after fosaprepitant treatment. To test whether 
the effect of fosaprepitant on IMR5 cells were specifically 
due to TACR1 inhibition, competition experiments with 
the TACR1 agonist, substance P were carried out. IMR5 
cells were incubated with 100 nM or 500 nM substance P 
1h before fosaprepitant treatment to saturate cell surface 
receptors. When incubated with substance P we observed 
a > 1.8 fold increase in the relative number of viable cells 
after fosaprepitant treatment (Figure  3D). However, even 
500 nM substance P was not able to reverse the effects 
of fosaprepitant in IMR5 cell lines to the full extent. 
This is consistent with the previously described higher 
binding efficiency of fosaprepitant to TACR1 [5, 18]. 
The partial reversibility of fosaprepitant-induced growth 
inhibition by nanomolar substance P concentrations as 
well as the differential activity of fosaprepitant on IMR5 
and SY5Y cells suggests selective targeting of TACR1 by 
fosaprepitant. The antiproliferative effects of fosaprepitant 
are largely selective for transformed cells, suggesting that 
off-target effects or general cytotoxicity in treated patients 
should be low. 
Figure 1: TACR1 and its downstream targets SRC and p-SRC are expressed in neuroblastoma cell lines. (A) Endogenous 
TACR1, SRC and p-SRC expression in whole-cell extracts of neuroblastoma cell lines was visualized by western blotting. GAPDH was 
used as a loading control. (B) Quantitative RT-PCR of TACR1 mRNA in a panel of neuroblastoma cell lines (n = 3, error bars indicate 
standard deviation). (C–E) Quantification of SRC (C), p-SRC (D) and TACR1 (E) protein expression using densitometry analysis of 
western immunoblots (n = 3, error bars indicate standard deviation). 
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TACR1 inhibition disrupts oncogenic gene 
expression signatures and induces gene sets 
associated with apoptosis
To gain further insight into the molecular basis for 
antitumor effects observed in vitro from fosaprepitant 
treatment, we analyzed gene expression in IMR5 cells 
following treatment with increasing concentrations 
of fosaprepitant or control. A clear dose-repose was 
apparent in expression profiles indicating a specific 
molecular mechanism underlying these expression 
changes (Figure  4A). Known oncogenes such as MYB 
and AURB were among the top downregulated genes 
following treatment (Figure  4A). To reveal potential novel 
downstream targets of TACR1 in neuroblastoma cells 
and understand the mechanisms through which TACR1 
inhibition leads to apoptosis in neuroblastoma cells, we 
interrogated our gene expression data with published, 
validated gene signatures to assess statistically significant 
enrichment by GSEA. Consistent with the phenotypic 
changes observed in neuroblastoma cells treated with 
fosaprepitant (Figures  2 and 3), the top 20 upregulated 
gene sets in IMR5 cells treated with fosaprepitant 
represented either pathways involved in apoptosis or cell 
Figure 2: Competitive inhibition of TACR1 with fosaprepitant leads to decreased cell viability and increased cell 
death in neuroblastoma cell lines. (A) MTT cell viability assay showing increased number of viable IMR5 neuroblastoma cells after 
treatment with TACR1 agonist substance P (100 nM and 500 nM, n = 3, error bars represent standard deviation, student’s t-test p < 0.05 for 
0 nM substance P vs. 100 nM substance P, p < 0.05 for 0 nM substance P vs. 500 nM substance P). (B) Dose-response of neuroblastoma cell 
line IMR5 (red) and non-transformed human fibroblasts (blue) after fosaprepitant treatment (n = 3, error bars represent standard deviation). 
(C) 50% Inhibitory concentration (IC50) of a panel of neuroblastoma cell lines and non-transformed fibroblast controls measured using 
MTT assays after treatment with 0–80 µM fosaprepitant. (D) Representative images of neuroblastoma cell cultures after 72 h of treatment 
with 5 µΜ fosaprepitant or Meglumine control (Scale bar = 100 µm). (E) BrdU incorporation ELISA assays showing decreased BrdU 
incorporation in neuroblastoma cell lines treated with fosaprepitant for 72 h in comparison with control-treated cells (n = 3, error bars 
represent standard deviation). (F) Cell death ELISA of neuroblastoma cell lines treated with fosaprepitant or control for 72 h, showing 
induction of cell death following treatment with fosaprepitant (n = 3, error bars represent standard deviation). For all figures, asterisk 
indicates p < 0.05 as calculated by student’s t-test. 
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cycle arrest, whereas the top 20 downregulated gene sets 
were enriched in gene sets involved in proliferation and 
progression through the cell cycle (Table 1). To identify 
common downstream effectors of TACR1 signaling, 
we searched for known regulons in the genes repressed 
after fosaprepitant treatment, and detected a significant 
enrichment of motifs bound by the E2F2 transcription 
factor (Table 2). This suggests E2F2 as a downstream 
target of TACR1. Consistent with this hypothesis, E2F2 
itself was repressed in a dose-dependent manner after 
fosaprepitant treatment (Figure  4B). Genes upregulated 
by fosaprepitant were also searched for regulons, and 
were enriched for TP53-binding motifs (Table 2). TP53 
expression was only slightly increased by fosaprepitant 
in IMR5 cells (Figure 4D, not significant), suggesting 
changes in TP53 activity rather than TP53 levels. Our 
analyses therefore suggests that TACR1 inhibition in 
neuroblastoma cells represses E2F2 and induces the pro-
apoptotic TP53 pathway, indicating that E2F2 and TP53 
may be downstream targets of TACR1 signaling. To test 
whether transcriptional changes translated into significant 
protein expression changes, we assessed AURB expression 
in cells treated with fosaprepitant or control. Consistent 
with the significant reduction in AURB mRNA expression, 
we observed a significant reduction of AURB protein 
in IMR5 and SK-N-AS cells following fosaprepitant 
treatment (Figure 4C). Previously published data 
suggested that SRC signaling is critical for the pro-tumoral 
activity of TACR1 [16]. We therefore tested the effect of 
TACR1 inhibition on SRC phosphorylation and expression 
in IMR5, SY5Y and SK-N-AS cells. P-SRC expression 
decreased significantly after 48 hours of fosaprepitant 
treatment in IMR5 and SK-N-AS cells whereas p-SRC 
did not decrease significantly in SY5Y cells, that in 
IMR5 and SK-N-AS cells TACR1 signals at least in part 
through SRC activation/phosphorylation (Figure  4C–4F). 
Figure 3: Inhibition of TACR1 with fosaprepitant leads to apoptosis and cell cycle arrest in neuroblastoma cell lines. 
(A) Representative flow cytometry images of IMR5, SK-N-AS and SY5Y cells treated with fosaprepitant or control for 72 h and stained 
for Annexin V and DAPI. Gates show viable cells (DAPI negative, Annexin V negative), early apoptotic cells (DAPI negative, Annexin 
V positive) and late apoptotic cells (DAPI positive, Annexin V positive) after treatment with fosaprepitant or control. (B) Proliferation of 
cells monitored in real time using the Xcilligance system after fosaprepitant treatment compared with cells treated with Meglumine control 
(n = 3, line represents mean value). (C) Fraction of cells in each point of the cell cycle measured after 48 h of treatment with fosaprepitant 
or meglumine (control). (D) Bar graph showing cell viability in MTT assays of IMR5 cells treated with 5 µM fosaprepitant or control for 
72 h as well as combined fosaprepitant and substance P treatment for 72 h (+ = 100 nM Substance P, ++ = 500 nM Substance P, n = 3, error 
bars represent the standard deviation)(100nM vs. no substance P, p = 0.0013; 500 nM vs. no substance P, p = 0.0006). 
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Table 1: Fosaprepitant treatment leads to significant and specific gene expression changes in 
TP53, EGFR and chemotherapy induced gene sets
Gene Set Rank Size NES FDR q-val
Upregulated 
ZHANG TLX TARGETS DN 1 66 2.56 0.00
PODAR RESPONSE TO ADAPHOSTIN UP 2 116 2.53 0.00
KERLEY RESPONSE TO CISPLATIN UP 3 29 2.50 0.00
SMIRNOV RESPONSE TO IR 6HR UP 4 133 2.45 0.00
KRIGE AMMINO ACID DEPRIVATION 5 25 2.41 0.00
KANNAN TP53 TARGETS UP 6 47 2.39 0.00
WARTERS RESPONSE TO IR SKIN 7 56 2.36 0.00
ZHANG TLX TARGETS 60HR UP 8 200 2.36 0.00
KOBAYASHI EGFR SIGNALING 24HR UP 9 69 2.33 0.00
CHANG CORE SERUM RESPONSE DN 10 148 2.29 0.00
WARTERS IR RESPONSE 5GY 11 31 2.29 0.00
MOLENAAR TARGETS OF CCND1 AND CDK4 UP 12 52 2.27 0.00
TIEN INTESTINE PROBIOTICS 24HR DN 13 189 2.26 0.00
ODONNELL TFRC TARGETS UP 14 225 2.25 0.00
GHANDHI DIRECT IRRADIATION UP 15 54 2.25 0.00
ZHANG TLX TARGETS 36HR UP 16 155 2.23 0.00
VARELA ZMPSTE24 TARGETS UP 17 29 2.23 0.00
RUIZ TNC TARGETS UP 18 106 2.21 0.00
ONDER CDH1 TARGETS 1 UP 19 92 2.21 0.00
PRAMOONJAGO SOX4 TARGETS UP 20 43 2.21 0.00
Downregulated
DUTERTRE ESTRADIOL RESPONSE 24HR UP 1 283 –3.44 0.00
ROSTY CERVICAL CANCER PROLIFERATION CLUSTER 2 136 –3.21 0.00
KOBAYASHI EGFR SIGNALING 24HR DN 3 223 –3.20 0.00
ZHANG TLX TARGETS 60HR DN 4 254 –3.17 0.00
FUJII YBX1 TARGETS DN 5 188 –3.12 0.00
ZHOU CELL CYCLE GENES IN IR RESPONSE 6HR 6 79 –3.08 0.00
SOTIRIOU BREAST CANCER GRADE 1 VS 3 UP 7 144 –3.06 0.00
SARRIO EPITHELIAL MESENCHYMAL TRANSITION UP 8 149 –3.03 0.00
MANALO HYPOXIA DN 9 272 –3.02 0.00
CROONQUIST IL6 DEPRIVATION DN 10 93 –3.00 0.00
ZHANG TLX TARGETS UP 11 84 –2.99 0.00
KONG E2F3 TARGETS 12 86 –2.99 0.00
BURTON ADIPOGENESIS 3 13 91 –2.98 0.00
BLUM RESPONSE TO SALIRASIB DN 14 320 –2.98 0.00
MOLENAAR TARGETS OF CCND1 AND CDK4 DN 15 54 –2.96 0.00
GRAHAM NORMAL QUIESCENT VS NORMAL DEVIDING DN 16 77 –2.95 0.00
ZHOU CELL CYCLE GENES IN IR RESPONSE 24HR 17 112 –2.93 0.00
CROONQUIST NRAS SIGNALLING DN 18 72 –2.91 0.00
ZHANG TLX TARGETS 36HR DN 19 176 –2.91 0.00
SHEDDEN LUNG CANCER POOR SURVIVAL A6 20 408 –2.90 0.00
Table of top 20 up- and down-regulated gene sets from the MSigDB C2 collection, enriched among genes induced by 
inhibition of the TACR1 based on GSEA (rank, rank of gene set in overall list of gene sets, ranked according to decreasing 
NES; size, number of genes in each set; NES, normalized enrichment score).
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Collectively, our results suggest that the antitumor effects 
induced by fosaprepitant in neuroblastoma cells may be 
due, at least in part, to decreased SRC phosphorylation 
leading to downstream E2F2 repression and that apoptosis 
might be induced via activation of pro-apoptotic TP53 
signaling.  
Fosaprepitant treatment lowers tumor burden in 
a human neuroblastoma xenograft mouse model
Having observed a robust, selective and specific 
antitumor effect in vitro, we analyzed the effect of 
TACR1 antagonist fosaprepitant in an in vivo model to 
test whether fosaprepitant could be useful in a clinically 
relevant context. Xenograft tumors were established 
subcutaneously from IMR5 cells in nude mice. Mice were 
randomly separated into control and treatment groups 
(n = 7) and subsequently intraperitoneally injected 
with 60 mg fosaprepitant/kg body weight/day or with 
dimeglumine as vehicle control. Consistent with previous 
reports, fosaprepitant was well tolerated by the mice and 
produced no significant side effects during the 14 days 
of treatment. Treatment with fosaprepitant significantly 
delayed xenograft tumor growth (Figure 5A and 5B)  In 
contrast to our in vitro observations, fosaprepitant was 
not able to stop tumor growth, suggesting reduced in vivo 
pharmacologic activity of fosaprepitant. To test whether 
fosaprepitant was able to induce apoptosis in IMR5 
xenografts, we assessed cleaved caspase-3 expression in 
three tumors treated with fosaprepitant or vehicle control. 
Consistent with the decreased anti-tumoral effects in 
vivo compared to in vitro, cleaved caspase-3 expression 
was only slightly increased in tumor treated with 
fosaprepitant compared to vehicle treated controls (Figure 
5C and 5D). Our results support that inhibiting TACR1 
with the antagonist, fosaprepitant, provides a therapeutic 
effect in a mouse model of neuroblastoma, and present 
fosaprepitant as a possible clinical avenue for patients with 
neuroblastomas with high-level TACR1 expression.
Pretreatment with fosaprepitant synergizes with 
cytotoxic chemotherapy in neuroblastoma cells
Considering the non-curative in vivo antitumoral 
activity of fosaprepitant observed (Figure  5), we decided 
to test whether combination treatment of fosaprepitant 
with cytotoxic agents could lead to greater anti-tumoral 
effects in neuroblastoma cells. To test this, we treated 
IMR5 cells with Doxorubicin and Etoposide, two 
established chemotherapeutic agents in use for patients 
with neuroblastoma. We tested co-treatment of IMR5 
cells with a chemotherapeutic agent and fosaprepitant for 
48 hours as well as pre- or posttreatment of fosaprepitant 
for 24 hours after/before 24 hours of treatment with a 
cytotoxic agent. Interestingly, pretreatment of cells with 
fosaprepitant before both Etoposide and Doxorubicin 
treatment showed synergistic anti-tumoral effects as 
evidenced by combinatorial indices (CI) below 1, 
indicating that fosaprepitant treatment leads to a relative 
sensitization of neuroblastoma cells to cytotoxic agents 
Table 2: Fosaprepitant leads to gene expression changes at a unique subset of transcription factor 
targets
Transcription factor NES #targets #motifs
Upregulated genes
TP53 5.65 86 6
FOXO4 5.20 117 35
NFYA 5.02 92 12
JDP2 4.40 80 8
MEIS1 3.74 52 4
HOXA13 3.63 44 3
Downregulated genes
E2F2 9.78 112 31
BRF1 3.70 32 2
TBP 3.54 40 5
KLF7 3.26 6 1
Table of transcription factors that bind to the motifs enriched among the genes up- and down-regulated upon administration 
of a low dose of the TACR1 antagonist to the IMR-5 cells (NES, normalized enrichment score, # targets, the number of 
merged targets found by numerous motifs, # motifs).
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(Figure 6A and 6B). Co-treatment as well as post-
chemotherapy treatment of cells with fosaprepitant, 
however, did not increase the antitumoral activity of 
these agents. These results indicate that scheduling of 
combination treatment with fosaprepitant and cytotoxic 
agents has significant effects on their antitumoral activity, 
which may be of clinical importance for patients receiving 
these agents.  
DISCUSSION
Here we show that human neuroblastoma cell lines 
express TACR1 and that blocking TACR1 activity using 
fosaprepitant robustly inhibits tumorigenic characteristics 
in both in vitro and in vivo neuroblastoma models. This is 
in line with previous reports by Munoz M. et al. describing 
anti-tumoral activity of fosaprepitant in various adult 
Figure 4: TACR1 inhibition by fosaprepitant leads to decreased SRC phosphorylation and is associated with dose-
dependent significant and specific gene expression changes. (A) Heatmap representation of top 50 dose-sensitive up- (red) and 
downregulated (blue) genes upon treatment of IMR-5 with fosaprepitant or control (heatmap representation generated by HeatmapViewer 
of GenePattern servers). (B) Dose-dependent mRNA expression changes of E2F2 and TP53 after treatment of IMR5 cells with fosaprepitant 
or control as measured using gene-expression arrays. (C) Western blot of published downstream effectors of TACR1 signaling, SRC 
and p-SRC, as well as the newly discovered potential downstream target AURB after treatment of IMR5, SY5Y and SK-N-AS with 
fosaprepitant or control. (D–F) Quantification of SRC (D), p-SRC (E) and TACR1 (F) protein expression using densitometry analysis of 
western immunoblots (n = 3, error bars indicate standard deviation, * indicates p < 0.05 and ** indicates p < 0.01 as calculated by student’s 
t-test).  
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tumor cell lines [10, 13, 14]. Similar to previous reports, 
we observed that inhibiting TACR1 with fosaprepitant did 
not affect all cell lines to the same degree. We observed 
that fosaprepitant reduced cell viability most strongly in 
cells expressing high levels of TACR1 and its downstream 
target p-SRC, i.e. exhibiting high TACR1 activity. 
Consistent with this, we also observed a more pronounced 
induction of cell death/apoptosis in cells expressing high 
levels of TACR1 and p-SRC, whereas cells expressing 
low levels of TACR1 and p-SRC underwent cell cycle 
arrest rather than cell death. TACR1 agonist substance P 
partially restored neuroblastoma cell viability, consistent 
with on target activity of fosaprepitant and in line with 
the previously reported stronger binding affinity of 
fosaprepitant to TACR1 [18]. Based on our data as well as 
previous reports, we conclude that the antitumoral activity 
of fosaprepitant is, indeed, due to selective TACR1 
inhibition, and that TACR1 expression as well as SRC 
phosphorylation in primary neuroblastoma samples may 
be predictive for fosaprepitant sensitivity. Together, our 
data extends previous knowledge about the mitogenic role 
of TACR1 in neuroblastoma and establishes TACR1 as a 
novel therapeutic target for neuroblastoma.  
There are only a few reports about the molecular 
functions of TACR1 and substance P in malignant cells, 
and little is known about downstream targets in the 
TACR1 signaling cascade [16, 19, 20]. TACR1 activation 
has previously been reported to result in phosphoinositide 
hydrolysis, calcium mobilization and subsequent calcium-
dependent signaling activation via kinases such as SRC 
[6, 7, 16]. We therefore investigated fosaprepitant-induced 
effects on these previously described targets downstream 
of TACR1 in neuroblastoma cells. Similar to previous 
reports in other tumor entities, we detected decreased SRC 
phosphorylation following TACR1 inhibition, indicating 
that in neuroblastoma TACR1 might at least in part signal 
through SRC. Consistent with decreased SRC signaling, 
expression of MYB, AURKB and PCNA was repressed 
in global gene profiles and genes involved in apoptosis 
(i.e. FAS) were upregulated. Global expression profiling 
also identified E2F2 and genes highly enriched for E2F2 
binding sites to be repressed. The dose dependency of 
fosaprepitant-induced gene expression changes suggests 
these are on-target effects. Genes containing TP53 
binding motifs were also dose-dependently increased 
following TACR1 inhibition indicating that TACR1 
signaling might directly affect TP53 pathway activity. 
Our global expression profiling also implicated TACR1 
in control of cell cycle progression and apoptosis in 
neuroblastoma cells, with TACR1 inhibition driving the 
Figure 5: Treatment with fosaprepitant decreases neuroblastoma tumor burden in a xenograft model. (A) Tumor 
volumes (mm3) of IMR5 xenografts in nude mice after treatment with fosaprepitant (60 mg/kg body weight per day) or control (n = 
7, error bars represent the standard deviation). (B) Tumor volume at day 14 after engraftment of IMR5 xenografts after treatment with 
fosaprepitant (60 mg/kg body weight per day) compared to control. (C) Western blot of cleaved caspase-3 in protein lysates from IMR5 
xenografts treated with fosaprepitant (60 mg/kg body weight per day)  or control (each column represents an independent biological 
replicate). (D) Quantification of cleaved caspase-3 protein expression using densitometry of western blots from IMR5 xenografts treated 
with fosaprepitant (60 mg/kg body weight per day) or control (p = 0.33 using an unpaired student’s t-test).
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cell towards apoptosis and cell cycle arrest. This is in line 
with our observation that cells treated with fosaprepitant 
undergo apoptosis and cell cycle arrest and is consistent 
with previous reports showing that TACR1 signaling 
plays important roles in controlling cell proliferation of 
various cell types, for review see Datar et al. [8]. It is 
still not entirely clear how TACR1 signaling affects these 
pathways. Previous reports and our current data, however, 
support the direct involvement of TACR1 signaling in 
regulating the E2F/TP53 signaling in neuroblastoma cells 
at least in part through activation of SRC. 
TACR1 antagonists have been previously described 
to have in vivo antitumoral activity against glioma and 
breast cancer xenografts [21, 22]. Similarly, we observed 
that intraperitoneal application of fosaprepitant in mice 
harboring neuroblastoma xenografts reduced tumor 
burden. Previous reports together with our current 
data suggest that fosaprepitant can exert significant 
therapeutic effects in vivo. However, the antitumor effect 
observed in our model as well as in previous reports 
was not curative, suggesting that higher fosaprepitant 
doses may be necessary to more efficiently combat the 
tumor. Alternatively, combining TACR1 antagonists with 
other therapeutic agents may also enhance antitumor 
efficacy. Considerable synergism between fosaprepitant 
and cytotoxic agents currently used in patients with 
neuroblastomas has been reported for osteosarcoma 
cells [13]. Similarly, we observed that fosaprepitant 
treatment synergized with doxorubicin and etoposide 
in neuroblastoma cells. Interestingly only pretreatment 
of cells with fosaprepitant followed by treatment with 
cytotoxic agents showed considerable synergy, indicating 
that fosaprepitant might sensitize cells to cytotoxic 
agents. This suggests that fosaprepitant might prime 
cells for apoptosis induced by cytotoxic agents, which 
is consistent with our observation that TP53 signaling 
was increased by fosaprepitant treatment and that TP53 
signaling is required for cytotoxic agent-induced cell death 
[23–25]. Considering that TP53 as well as AURB were 
induced by fosaprepitant treatment in our experiments, 
agents activating or stabilizing TP53 as well as AURB 
kinase inhibitors may also act synergistically with TACR1 
inhibitors in neuroblastoma.  
Intravenous administration of 115 mg fosaprepitant 
in patients results in peak concentrations of 5 µM 
circulating in blood and doses of up to 1000 mg have been 
administered to adults without significant side effects [5]. 
Furthermore, fosaprepitant has been successfully used 
as an antiemetic in combination with cytotoxic agents 
such as carboplatin without significant side effects [3]. 
Based on this, we believe that administering fosaprepitant 
to patients in parallel with chemotherapeutic agents 
currently used for first-line therapy of neuroblastoma 
should be well tolerated. Considering we observed IC
50
 
Figure 6: Pretreatment of neuroblastoma cells with fosaprepitant synergizes with cytotoxic chemotherapy. A+B Synergy 
between fosaprepitant and doxorubicin (A) and etoposide (B) was quantified by Combination Index (CI) analysis vs. fraction affected 
using CompuSyn (http://www.combosyn.com/). By this method, CI < 1 indicates synergy; CI = 1 indicates an additive effect; and CI > 1 
indicates antagonism. Synergy was calculated based on MTT assays of IMR5 cells: i. co-treated with fosaprepitant and doxorubicin (A) 
or etoposide (B) for 48 hours (left), ii. treated with fosaprepitant for 24 hours followed by 24 hours of doxorubicin (A) or etoposide (B) 
treatment (middle) or iii. treated with doxorubicin (A) or etoposide (B) for 24 hours followed by fosaprepitant treatment for 24 hours (right).
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concentrations ranging between 0.85 µM and 21.09 µM 
for neuroblastoma cell lines in vitro, fosaprepitant may 
have a therapeutic index in patients with neuroblastoma. 
In summary, the anti-neuroblastoma activity observed 
in our mouse model and the previously reported good 
pharmacological properties in patients suggest that 
fosaprepitant has the potential to generate a measurable 
response in combination with current treatment regimens 
in patients with high-risk neuroblastoma, and thus, should 
be considered for entry into clinical testing.  
MATERIALS AND METHODS
Reagents and cell culture
All reagents were obtained from Sigma Aldrich if 
not otherwise specified (Sigma Aldrich, St. Louis, MO, 
USA). The identity of the human neuroblastoma cell 
lines, IMR5, SK-N-BE, SK-N-AS, SY5Y and Kelly, and 
foreskin fibroblasts were verified by STR genotyping 
performed by the German Collection of Microorganisms 
and Cell Cultures (DSMZ, Braunschweig, Germany). Cell 
lines were cultured at 37°C in a humidified atmosphere, 
with 5% CO
2
 in RPMI 1640 supplemented with 10% 
fetal calf serum, 1% L-glutamine, and 100 U penicillin/
streptomycin per ml medium. Substance P and acetate 
salt (Sigma-Aldrich) were dissolved in distilled water to 
10 mM (stock solution) and diluted to 5, 10, 50, 100 and 
500 nM in full medium for experiments. In experiments 
investigating synergistic or competing effects, the IMR5 
cell line was incubated 1 h with substance P before 
adding other treatments. Fosaprepitant (IVEMEND) was 
dissolved in 0.9% NaCl for a 10 mM stock solution that 
was aliquoted for single use in both cell culture and mouse 
experiments and stored at 4°C. Meglumine (dissolved in 
0.9% NaCL to 10 mM and stored at 4°C) was used for 
control cell cultures and mice, since it is the most abundant 
substance in fosaprepitant powder after the active agent. 
Viability, proliferation and cell death 
quantification
Cell lines were seeded onto 96-well plates (2 × 103 
per well) in at least triplicate for all assays, and incubated 
for 24 h to permit surface adherence. Concentrations of 
1–100 µM fosaprepitant were prepared by serial dilution 
in complete medium, and cell viability was assessed 
in time course after 24 h, 48 h, 72 h, 96 h and 120 h of 
treatment using the Cell proliferation, MTT assay (Roche, 
Basel, Switzerland), according to the manufacturer’s 
protocol. Absorbance was read at 570 nm on an AD340 
plate reader. Growth inhibition dose-response curves were 
plotted as a percentage of untreated control cells. Fifty 
percent inhibition of growth (IC50) and 95% confidence 
interval (CI) were calculated using GraphPad Prism 
5.0 (GraphPad Software Inc., San Diego, CA, USA). 
Apoptosis and proliferation were assessed after 48 h 
and 72 h of treatment with 25 μM fosaprepitant using 
the Cell Death Detection ELISA and Cell proliferation 
BrdU ELISA (Roche) assays (Roche, Basel, Switzerland) 
according to manufacturer’s instructions. For FACS-based 
cell cycle analyses, cell lines were cultured for 24–72 h 
with 10 µM or 25 µM fosaprepitant or 425 µM meglumine 
as a control in 22 mm plates initially seeded with 1 × 105 
cells/plate. Cells were trypsinized, washed 3 times with 
phosphate-buffered saline, then incubated with DAPI 
and Annexin V (ANXA5) as previously described [26] 
before analysis on a FC500 flow cytometer (Beckman 
Coulter). All experiments were independently performed 
3 times, unless otherwise indicated. Experiments to assess 
substance P competition of fosaprepitant treatment were 
conducted using IMR5 cells seeded into 96-well plates at 
3000 cells/well. Substance P was added 24 h after seeding, 
and fosaprepitant was added 1 h later, then cell viability 
was measured after 72 h of treatment using the MTT assay, 
as described above. To assess cellular survival in real-time 
using the Xcelligence system (Roche, Basel, Switzerland), 
cells were plated in triplicate at 2 × 103 cells/well onto 
96-well Xcelligence microelectronic cell sensor plates, 
and cultured overnight in antibiotic-free complete media. 
Cells were treated with Fosaprepitant (5 µM, 10 µM or 
25 µM) or Meglumine vehicle control, then adherence to 
the culture plates was continuously monitored for 190h to 
assess cellular survival. For cell cycle analysis, cell lines 
were cultured 48h with Fosaprepitant (10 µM or 25 µM) 
or Meglumine control in 35mm plates at 5 × 107 cells/
plates. Cells were removed by trypsinization and washed 
3 times with PBS, then incubated with propidium iodide 
for 15 min to stain DNA. Cellular DNA content was 
analyzed in an FC500 flow cytometer (Beckman Coulter). 
All experiments were independently performed at least 
3 times, if not otherwise indicated.
Western blot analysis
Protein lysate preparation and western blotting was 
carried out as described previously (13) using primary 
antibodies against TACR1 (1:500, NB300-119, Novus 
biologicals, R&D Systems GmbH, Wiesbaden, Germany), 
SRC (1:500, #2108, Cell signaling technologies, Danvers, 
MA, USA), p-SRC (1:500, #2101, Cell signaling 
technologies), Actin (1:5000, #3700, Cell signaling 
technologies), AURKB (1:2000, ab45145, Abcam, 
Germany) and GAPDH (1:2000, MAB374, Millipore). 
After washing twice with 0.1% Tween 20 in Tris-buffered 
saline, pH = 7.5 (TBS-T), membranes were incubated 1h 
at room temperature with either horseradish peroxidase-
conjugated anti-mouse IgG (#NA9310V; GE Healthcare, 
Solingen, Germany), anti-rabbit IgG (#NA9340V; GE 
Healthcare) or anti-sheep IgG (#HAF016; R&D Systems), 
diluted 1:2000 in 5% nonfat dry milk in TBS-T. Proteins 
were visualized using the ECLplus western blotting 
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detection kit (GE Healthcare) and analyzed on the 
FusionFX7 detection device (Peqlab, Erlangen, Germany). 
Densitometry analysis was performed using ImageJ 
according to the programs recommendations (https://
imagej.nih.gov).
Quantitative RT-PCR analysis
Quantitative RT-PCR analysis was done as 
previously described [27]. In short, total RNA was 
isolated from cells using the RNeasyMini kit (Qiagen, 
Hilden, Germany), and cDNA synthesis was performed 
using the SuperScript reverse transcription kit according 
to the manufacture’s protocol (Invitrogen, Darmstadt, 
Germany). TACR1 expression were monitored using 
Assays-on-Demand™ (Applied Biosystems, Foster 
city,CA, USA). Expression values were normalized to the 
geometric mean of GAPDH [28]. Data analysis and error 
propagation were performed using the qbasePLUS software 
version 1.5 (http://www.biogazelle.com).
Microarray expression analysis
IMR5 cells were plated at 2 × 105 cells/well in 
6-well plates, left for 12 h to attach, then treated in 
triplicate with medium containing 425 µM meglumine 
(control) or 10 µM or 25 µM fosaprepitant for 24 h. 
Total RNA was extracted using the RNeasyMini kit 
(Qiagen, Hilden, Germany), and samples profiled on 
the HG-U133 Plus 2.0 Human Gene Expression Array 
(Affymetrix, Santa Clara, CA, USA) at the Centre for 
Medical Biotechnology, University Hospital Essen using 
established protocols. 
Data analysis 
For microarray based gene-expression analysis, 
microarray CEL files were normalized and summarized 
over probes for gene expression using the Bioconductor 
gcRMA normalization tool in R [29]. Probes for which 
log2 expression was < 4 in 7 of 8 samples, were considered 
underexpressed and not used in analyses, leaving a total 
of 11568 unique genes for analysis. Ward-Manhattan 
clustering of the 300 probes with the highest standard 
deviation over all selected samples was performed to 
evaluate the similarity between samples. Differential 
expression was analyzed using Rank-Product analysis in R 
(v 2.13, RankProd package) [30]. Hierarchical clustering 
on Manhattan distance of log2 expression values of the 
50 most differentially expressed genes was applied to 
visualize differential gene expression after treatment. 
Regression analysis with FDR correction for multiple 
testing was used to identify genes increasing or decreasing 
in expression over the applied concentration range, and 
genes with a log2 fold-change of at least 1 between the 
highest treatment concentration and control condition were 
considered as differentially expressed. In practice, this was 
detected by a regression line for a gene with a slope > 0.4 
or < −0.4, which indicated gene up- or downregulated, 
respectively. To gain insight into transcriptional programs 
downstream of TACR1 receptor signalling, iRegulon 
analysis, a Cytoscape plugin to identify regulons in a set of 
co-regulated genes using motif discovery, was performed 
on up- and downregulated genes [31]. A regulon consists 
of a transcription factor and its direct transcriptional 
targets, which contain common transcription factor 
binding sites in their cis-regulatory control elements. Gene 
set enrichment analysis was performed using the c2.cgp.
v3.1.symbols.gmt gene set and GSEA v2.0 software from 
www.broadinstitute.org/gsea [32]. Genes were rank-
ordered using a signal-to-noise ranking metric that scales 
the difference of means in the populations to be compared 
using the standard deviation. 
Fosaprepitant treatment of neuroblastoma 
xenograft tumors in nude mice 
IMR5 cells were cultured to 80% confluence, 
harvested and suspended in 200 µl Matrigel™ (BD 
Bioscience, Heidelberg, Germany) for subcutaneous 
inoculation (2 × 107 cells per mouse) into the left 
flank of 6-week-old female athymic (nu/nu) mice. 
Mice were randomly assigned to vehicle control or 
fosaprepitant groups (n = 7 mice per group) after tumors 
had clearly progressed and reached 150  200 mm3 in 
size. Fosaprepitant was administered by intraperitoneal 
injection at 60 mg/kg body weight (BW) daily. Vehicle 
controls were treated with meglumine in 0.9% NaCl 
(60 mg/kg BW daily). Tumor growth was monitored 
using calipers and tumor volume was calculated using the 
formula (width × length × height)/2. Mice were sacrificed 
by cervical dislocation after 15 days of treatment. All 
animal experiments were performed in accordance with 
the Council of Europe guidelines for housing and care of 
laboratory animals, and protocols were approved by the 
Ethical Commission for Animal Experimentation at the 
University Hospital Essen.
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